Drugs / G-CSF mobilized peripheral blood mononuclear cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07297173 | Dec 2025 → Dec 2028 expected | leukemia | Beijing 302 Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-CSF mobilized peripheral blood mononuclear cell | “This is a Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of chemotherapy combining with HLA-mismatched G-CSF mobilized...” NCT07297173 ↗ |
| Known as | GPBMC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07297173 ↗ |
| Modality | Cell therapy | “Biological: HLA-mismatched GPBMC infusion” NCT07297173 ↗ |
| Route | Other | “HLA-mismatched GPBMCs are infused following chemotherapy.” NCT07297173 ↗ |